Hengrui Pharma(SH:600276) BOHAI SECURITIES·2025-12-12 09:22Investment Rating - The report maintains an "Optimistic" rating for the industry and a "Buy" rating for Heng Rui Medicine (600276) [52] Core Insights - The newly released basic medical insurance drug directory and the first commercial health insurance innovative drug directory support the development of innovative drugs and promote the complementary relationship between commercial health insurance and basic medical insurance [9][12] - A total of 114 new drugs have been added to the directory, including 50 first-class innovative drugs, while 29 drugs have been removed due to lack of clinical supply or better alternatives [11][12] - The report emphasizes the importance of monitoring the volume growth of pharmaceutical companies' products after entering the insurance directory and the investment opportunities arising from the optimization of payment structures for innovative drug companies [51] Industry News - The new basic medical insurance drug directory and the first commercial health insurance innovative drug directory were published, with the new directory set to take effect on January 1, 2026 [9] - The first commercial health insurance innovative drug directory includes 19 drugs, which complement the basic medical insurance and support the establishment of a multi-tiered medical security system [12] - The first CDK2/4/6 inhibitor developed by China Biopharmaceutical has been approved for market launch, indicating advancements in innovative drug development [14] Company Announcements - Heng Rui Medicine has successfully included several drugs in the national medical insurance directory through negotiations, enhancing its market position [31] - Stone Pharmaceutical Group has received acceptance for its second marketing authorization application for Semaglutide injection [29] - Junshi Biosciences has had its new drug application for the injection of Nocadizumab accepted [32] Market Review - For the week of December 5 to December 11, 2025, the SW Pharmaceutical and Biological Index fell by 0.78%, with most sub-sectors experiencing declines [40] - As of December 11, 2025, the SW Pharmaceutical and Biological Industry's price-to-earnings ratio (TTM) was 50.70, with a valuation premium of 265% relative to the CSI 300 [44] Weekly Strategy - The report suggests focusing on the growth potential of pharmaceutical companies' products after entering the insurance directory and the investment opportunities in the CXO and upstream life sciences sectors [51]